康方生物再传喜讯!PD-1在美拿下两项适应症

国际金融报
25 Apr

4月25日盘前,港股上市公司康方生物宣布,其PD-1单抗派安普利(商品名:安尼可)获美国食品药品监督管理局(FDA)批准两项适应征,用于治疗晚期鼻咽癌。值得注意的是,这是首个由中国公司全过程独立主导(研发,临床,生产供药和申报注册)且成功获得FDA批准上市的创新生物药。该药最初由康方生物研发,随后同港股上市公司中国生物制药旗下公司正大天晴合作,由正大天晴康方负责后续的开发和商业化。同时,康方生物的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10